Riyaz Abidi Poster PDF

Overcoming Obesity Through Glucagon-Like Peptide 1 (GLP-1) Receptor Co-Agonist Drugs Riyaz Abidi Dr. Syed W. Rizvi, MD • Evaluate the efficacy of GLP-1 on obesity Co-Agonist drugs through a retrospective study • Understand the effects of GLP-1 Co- Agonist Drugs on weight/BMI • Educate the populace on obesity, and find solutions like using GLP-1 Co- Agonist drugs to put an end to obesity • In 2013 the American Medical Association classified Obesity (grossly fat/overweight by the 85th-95 th BMI percentile) as a disease • According to CDC 78.6 million Americans are Obese – 70.7% adults (ages 20+) and 46.6% children (ages 2- 19) • GLP-1 Co-Agonist Drugs control Glucose levels and storage in the body and increase metabolism • Collect data on existing patients currently on GLP-1 Co-Agonists EMR Software • Export, and organize data in a spreadsheet - run SPSS Correlations • Analyze the data • Some patients were lost in the study because not all data was recorded for them • The mean and median for the BMI were shown to be lower after the use of GLP-1 Co-Agonists • There is a strong positive correlation between the BMI before and the BMI after the use of GLP-1 Co- Agonists • Evaluations performed were distributed to better understand the use of GLP-1 Co- Agonist drugs for obese patients • Presentations by Pharmaceutical representatives and physicians are held to evaluate data and formulate recommendations to patients on the usage of the GLP-1 Co-Agonists • Educate the populace on obesity as a serious disease and its adverse effects • Ensure people understand the benefits of GLP-1 Co-Agonists • Promote GLP-1 Co-Agonists as a solution to overcome Obesity • Create balanced nutritional diet charts and exercise schedules for targeted populations struggling with Obesity • Conduct more research to help promote the usage of GLP-1 Co-Agonist In Collaboration With: Special thank you to: Dr. Syed W. Rizvi, MD- Endocrinologist Sakina Rizvi, Assistant Representative UN Professor Ann Marie Hill Purpose Methodology Evaluation Acknowledgments Recommendations Outcomes Significance Planning Collect Data Organization Analysis

Upload
riyaz-abidi
Category

Documents
view
50
download
3

Embed Size (px):

Transcript of Riyaz Abidi Poster PDF

OvercomingObesityThroughGlucagon-LikePeptide1(GLP-1)ReceptorCo-AgonistDrugs

Riyaz AbidiDr.SyedW.Rizvi,MD

• Evaluate the efficacy of GLP-1 on obesity Co-Agonist drugs through a retrospective study

• Understand the effects of GLP-1 Co-Agonist Drugs on weight/BMI

• Educate the populace on obesity, and find solutions like using GLP-1 Co-Agonist drugs to put an end to obesity

• In 2013 the American Medical Association classified Obesity (grossly fat/overweight by the 85th-95th BMI percentile) as a disease

• According to CDC 78.6 million Americans are Obese – 70.7% adults (ages 20+) and 46.6% children (ages 2-19)

• GLP-1 Co-Agonist Drugs control Glucose levels and storage in the body and increase metabolism

• Collect data on existing patients currently on GLP-1 Co-Agonists EMR Software

• Export, and organize data in a spreadsheet - run SPSS Correlations

• Analyze the data

• Some patients were lost in the study because not all data was recorded for them

• The mean and median for the BMI were shown to be lower after the use of GLP-1 Co-Agonists

• There is a strong positive correlation between the BMI before and the BMI after the use of GLP-1 Co-Agonists

• Evaluations performed were distributed to better understand the use of GLP-1 Co-Agonist drugs for obese patients

• Presentations by Pharmaceutical representatives and physicians are held to evaluate data and formulate recommendations to patients on the usage of the GLP-1 Co-Agonists

• Educate the populace on obesity as a serious disease and its adverse effects

• Ensure people understand the benefits of GLP-1 Co-Agonists

• Promote GLP-1 Co-Agonists as a solution to overcome Obesity

• Create balanced nutritional diet charts and exercise schedules for targeted populations struggling with Obesity

• Conduct more research to help promote the usage of GLP-1 Co-Agonist

In Collaboration With:

Special thank you to:

Dr. Syed W. Rizvi, MD- Endocrinologist

Sakina Rizvi, Assistant Representative UN

Professor Ann Marie Hill

Purpose

Methodology EvaluationAcknowledgments